Especially, we discovered a highly selective DYRK2 inhibitor with favorable druggability, which could be used as a small-molecule probe for biological studies and also provide a potential candidate for PCa clinical treatment. This evidence concerns the gene DYRK2 and posterior cortical atrophy.